You are here

eczema

Novartis dumps Ziarco eczema drug, taking $485M hit

Novartis dumps Ziarco eczema drug, taking $485M hit

Fierce Biotech

Flag link:

LEO eyeing 2021 US launch for eczema drug tralokinumab

LEO eyeing 2021 US launch for eczema drug tralokinumab

Pharmaforum

Flag link:

AAD 2020 – Leo’s eczema wildcard proves tame

AAD 2020 – Leo’s eczema wildcard proves tame

EP Vantage

atopic dermatitis

Flag link:

Pfizer's JAK abrocitinib comes through in teen eczema test

Pfizer's JAK abrocitinib comes through in teen eczema test

Fierce Biotech

atopic dermatitis

clinical trials

Flag link:

New safety data expose potential weakness as Pfizer's abrocitinib takes on Dupixent in eczema

New safety data expose potential weakness as Pfizer's abrocitinib takes on Dupixent in eczema

Endpoints

clinical trials

Flag link:

LEO Pharma mounts another challenge to the eczema giants, betting $40M cash on a drug from China

LEO Pharma mounts another challenge to the eczema giants, betting $40M cash on a drug from China

Endpoints

clinical trials

Flag link:

Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema

Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema

Motley Fool

clinical trials

atopic dermatitis

Flag link:

Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug

Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug

TheStreet.com

clinical trials

Flag link:

Dermira shares double on positive eczema data

Dermira shares double on positive eczema data

Biopharma Dive

clinical trials

Flag link:

Upcoming events – Ascendis and Lilly hope for growth with pivotal data

Upcoming events – Ascendis and Lilly hope for growth with pivotal data

EP Vantage

clinical trials

pediatric growth hormone deficiency

Flag link:

Hoth Therapeutics seeks IPO cash to battle eczema

Hoth Therapeutics seeks IPO cash to battle eczema

Fierce Biotech

Hoth Therapeutics

Flag link:

Sanofi unveils eczema drug data, as regulators mull label expansion

Sanofi unveils eczema drug data, as regulators mull label expansion

Pharmaforum

atopic dermatitis

Flag link:

Zai Lab bombs Phase IIa trial in atopic dermatitis, junks the program to shift resources to the pipeline

Zai Lab bombs Phase IIa trial in atopic dermatitis, junks the program to shift resources to the pipeline

Endpoints

clinical trials

Flag link:

2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?

2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?

Motley Fool

Flag link:

Sanofi and Regeneron's Dupixent launch is about to get a cash infusion

Sanofi and Regeneron's Dupixent launch is about to get a cash infusion

Fierce Pharma

Flag link:

Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status

Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status

Fierce Pharma

Flag link:

Dermira Commits $135M for Global Rights to Roche Eczema Drug

Dermira Commits $135M for Global Rights to Roche Eczema Drug

Xconomy

Flag link:

Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat

Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat

Fierce Pharma

Flag link:

Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent

Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent

Fierce Pharma

Flag link:

Just what Sanofi and Regeneron wanted: A Dupixent rollout so zippy, it's fueling bigger sales forecasts

Just what Sanofi and Regeneron wanted: A Dupixent rollout so zippy, it's fueling bigger sales forecasts

Fierce Pharma

Flag link:

Pages